Corticosteroid-Only Arm Worth Public Health Risk In Antifungal Trials - Cmte.
Executive Summary
The benefits of studying a stand-alone corticosteroid arm in a trial comparing an antifungal/corticosteroid combination to an antifungal outweigh public health concerns raised by patient exposure to the corticosteroid, FDA's Dermatologics & Ophthalmics Committee concluded.
You may also be interested in...
Schering Lotrisone Warnings Should Be Milder, FDA Committee Says
Schering-Plough Lotrisone labeling should sufficiently warn against use of the drug in children under 12 but should not be so severe that physicians who use it off label for valid reasons are intimidated, FDA's Dermatologics & Ophthalmics Advisory Committee said.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials